94 results
Page 4 of 5
8-K
EX-99.1
7titpicp1s14sjwi4
15 May 20
INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update
9:06am
8-K
EX-99.1
ao9g i35w
21 Apr 20
Other Events
4:10pm
8-K
EX-1.1
lk4dsxtp8e
17 Apr 20
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.2
nicmlw pakdj7px8m
9 Apr 20
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB INVESTOR PRESENTATION 2Q 20 V1
5:30pm
8-K
EX-99.1
jnq1a0ok5ubhrplww34
9 Apr 20
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB INVESTOR PRESENTATION 2Q 20 V1
5:30pm
8-K
EX-99.1
fvepb9d 9iru48
12 Mar 20
INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer’s Disease and NASH
4:04pm
8-K
EX-10.1
wd82fggbd5 vtrbl
10 Feb 20
INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS
9:22am
8-K
EX-99.1
0r2iof0 b430
17 Dec 19
Regulation FD Disclosure
4:53pm
8-K
EX-99.1
nl34o mrupxforlk99i
3 Dec 19
INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
4:06pm
8-K
EX-99.1
0kxukz7w
12 Sep 19
Inmune Bio Inc. Announces Uspto Allowance of Key Patent Covering Its DN-TNFΑ Platform Technology for Treating Cancer
4:30pm
8-K
EX-99.1
lsmvk
9 Sep 19
Regulation FD Disclosure
4:31pm
8-K
EX-99.1
m04ytzyw
27 Aug 19
Regulation FD Disclosure
5:00pm
8-K
EX-99.1
3qk8n8 th
15 Aug 19
Regulation FD Disclosure
12:00am
8-K
EX-99.1
e4m4e25d4mase zb
13 Aug 19
INmune Bio Reports Second Quarter 2019 Financial Results and Provides Shareholder Update
4:36pm
DEF 14A
9511s1 977ahg2z3
9 Aug 19
Definitive proxy
4:58pm
8-K
EX-99.1
ycoep
7 Aug 19
INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer
4:30pm